Relay Therapeutics (RLAY) Current Deferred Revenue (2021 - 2024)
Relay Therapeutics (RLAY) posted quarterly Current Deferred Revenue of $7.7 million for Q4 2024, up 31895.83% quarter-over-quarter from $24000.0 in Q3 2023.
Relay Therapeutics (RLAY) Current Deferred Revenue (2021 - 2024) Analysis & Trends
Relay Therapeutics (RLAY) has reported Current Deferred Revenue for 4 consecutive years, with $7.7 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Current Deferred Revenue changed N/A year-over-year to $7.7 million; the TTM figure through Dec 2024 stood at $7.7 million (changed N/A YoY), while the FY2024 annual figure was $7.7 million, changed N/A from the prior year.
- Current Deferred Revenue improved to $7.7 million in Q4 2024 per RLAY's latest filing, from $24000.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $7.7 million in Q4 2024 and bottomed at $15000.0 in Q2 2023.
- Historically, Current Deferred Revenue has averaged $1.1 million across 4 years, with a median of $207000.0 in 2021.
- Annual changes were most pronounced in 2022 — Current Deferred Revenue plunged 79.95% — and 2023, when it sank 81.93%.
- Relay Therapeutics' Current Deferred Revenue stood at $248000.0 in 2021, then plunged by 66.53% to $83000.0 in 2022, then tumbled by 71.08% to $24000.0 in 2023, then jumped by 31895.83% to $7.7 million in 2024.
- Business Quant data shows RLAY's Current Deferred Revenue at $7.7 million in Q4 2024, $24000.0 in Q3 2023, and $15000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Relay Therapeutics | 4.34 Bn | 4.34 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 7.68 Mn |
| Sep 30, 2023 | 24,000.00 |
| Jun 30, 2023 | 15,000.00 |
| Jun 30, 2022 | 83,000.00 |
| Mar 31, 2022 | 166,000.00 |
| Dec 31, 2021 | 248,000.00 |
| Sep 30, 2021 | 331,000.00 |
| Jun 30, 2021 | 414,000.00 |